Clinical trial
A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec� (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphobla
To characterize the pharmacokinetics of imatinib in pediatric patients age 1 to less than 4 years via appropriate integrated physiologically-based pharmacokinetic (PBPK) and population pharmacokinetics (pop PK) approaches.
| Category | Value |
|---|---|
| Study start date | 2010-03-09 |